Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
234.5(c) 234.7(c) 234.5(c) 234.5(c) 235(c) Last
864 448 1 336 188 950 678 564 940 1 512 778 Volume
-0.04% +0.09% -0.09% 0.00% +0.21% Change
More quotes
Estimated financial data (e)
Sales 2021 14 941 M 1 736 M 1 736 M
Net income 2021 2 099 M 244 M 244 M
Net Debt 2021 9 618 M 1 118 M 1 118 M
P/E ratio 2021 33,2x
Yield 2021 -
Sales 2022 15 989 M 1 858 M 1 858 M
Net income 2022 2 215 M 257 M 257 M
Net Debt 2022 6 510 M 756 M 756 M
P/E ratio 2022 31,4x
Yield 2022 -
Capitalization 69 359 M 8 055 M 8 059 M
EV / Sales 2021 5,29x
EV / Sales 2022 4,74x
Nbr of Employees 1 537
Free-Float 59,5%
More Financials
Company
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The CompanyÔÇÖs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Ratings of Swedish Orphan Biovitrum AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
10/15APELLIS PHARMACEUTICALS : Swedish Orphan Biovitrum Say PNH Treatment Candidate Aspaveli Re..
MT
10/15SWEDISH ORPHAN BIOVITRUM : Blood Disease Drug Gets EU's Positive Opinion
MT
10/15SWEDISH ORPHAN BIOVITRUM : Aspaveli« (pegcetacoplan) receives positive CHMP opinion for tr..
AQ
10/12SWEDISH ORPHAN BIOVITRUM : Sweden's Sobi Raises Lower End Of FY21 Revenue Guidance
MT
10/11SWEDISH ORPHAN BIOVITRUM : Drugmaker SOBI sees Q3 operating profit at 1.17 billion crowns,..
RE
10/11SWEDISH ORPHAN BIOVITRUM : Sobi announces preliminary headline numbers for the third quart..
AQ
10/11Swedish Orphan Biovitrum AB Provides Financial Outlook for the Full Year 2021
CI
10/11Swedish Orphan Biovitrum AB Provides Earnings Guidance for the Third Quarter and Nine M..
CI
10/08SWEDISH ORPHAN BIOVITRUM : EU, Turkey Green-light Advent, GIC's Sobi Acquisition
MT
10/07SWEDISH ORPHAN BIOVITRUM : EU OKs Advent International's Sole Control Of Swedish Orphan Bi..
MT
10/04SELECTA BIOSCIENCES : Signs Deal with Takeda Worth Up to $1.12 Billion for Next-Generation..
MT
09/30SWEDISH ORPHAN BIOVITRUM : New number of shares and votes in Swedish Orphan Biovitrum AB (..
AQ
09/07SWEDISH ORPHAN BIOVITRUM : Nature Medicine publishes positive phase 3 anakinra study resul..
AQ
09/07Swedish Orphan Biovitrum AB Publishes Positive Phase 3 Anakinra Study Results in Patien..
CI
09/03STUDY : Swedish Orphan Biovitrum's Save-More Treatment Effective Against COVID-19 Pneumoni..
MT
More news
News in other languages on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
10/15Le médicament orphelin suédois Biovitrum contre les maladies du sang reçoit l'avis favo..
10/12Le suédois Sobi relève la limite inférieure de ses prévisions de revenus pour l'exercic..
10/11Le fabricant de médicaments SOBI enregistre un bénéfice d'exploitation de 1,17 milliard..
10/11L'entreprise suédoise Orphan Biovitrum AB (publ) fournit des perspectives financières p..
10/11L'entreprise suédoise Orphan Biovitrum AB (Publ) fournit des prévisions de résultats po..
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
More recommendations
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | SOBI | SE0000872095 | MarketScreener
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 235,00 SEK
Average target price 219,63 SEK
Spread / Average Target -6,54%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Hňkan Bj÷rklund Chairman
Anne Marie de Jonge Schuermans Head-Technical Operations
Ravi Madduri Rao Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SWEDISH ORPHAN BIOVITRUM AB (PUBL)41.48%8 055
CSL LIMITED5.08%100 638
WUXI BIOLOGICS (CAYMAN) INC.6.42%59 673
SAMSUNG BIOLOGICS CO.,LTD.5.21%48 619
BIOGEN INC.16.50%41 907
ALEXION PHARMACEUTICALS, INC.0.00%40 336